Just to add to what itsupfromhere says, most institutional ownership doesn't come from the float. They are either allocated shares from the IPO (to make the book), or from shelf placements, or from secondary offerings. But they'll buy from the open market if the price is right, and if the float is large enough for the price to hold up in a sale (unless their intent is to manipulate the price buy manipulating a small float)
This deal will get done. Shire has gone hostile on Baxalta, and Baxalta doesn't have the time to start this process over on another company. They'll pay a few hundred to get it done in order to derail Shire.
Can you please post a link that documents this? Thank you!
"The FACT that the co-therapy of SD-101 and a PD-1 inhibitor resulted in a PERFECT 100% SURVIVAL and 100% COMPLETE REMISSIONS in pre-clinical studies against melanoma..."
Hey, bourbon on cornflakes may be gross, but bourbon definitely knows his Swiss. I spent years 13-16 in a Swiss boarding school in Fribourg (not Freiburg, which is in Germany, mind you), and those are indeed the four languages the Swiss speak...well... You can make it five and a half, because most Swiss speak English, and most speak both proper German as well as their Switze-Deutch (which I may have misspelled! But back to AVXL. I'm sure I'm not the only one that was in PRAN, or a myriad of other names that have failed in AD. Nonetheless, I'm intrigued with the synergy between Donepezil and 2-73, even though it didn't work with memantine (two different mechanisms of action). Both are $2 billion drugs, roughly speaking, but NIH says Donepezil is slightly more cost-effective, so if the 4x 2-73+Donepezil scores hold up over Donepezil alone, we are in big business. But as I've suggested, this is highly speculative stuff, so make sure you know what your #$%$ looks like so you know what you'd be losing, just in case. ;-)